The multiple-kinase inhibitor lenvatinib inhibits the proliferation of acute myeloid leukemia cells.

ABSTRACT:

Background

Current chemotherapy for acute myeloid leukemia (AML) mainly involves cytotoxic agents such as doxorubicin (DNR), mitoxantrone (Mito) or 2-aminopurine-6-thiol (6-TG). However, because these agents are relatively ineffective, discovering other more effective drugs for AML treatment would be valuable.

Methods

The in vitro antitumor effect of lenvatinib on AML cells was examined using the colorimetric MTT assay for assessing cell metabolic activity. AML cells mixed with Poloxamer 407 were injected into nude mice to form subcutaneous tumors. Tumor-bearing mice received lenvatinib by oral administration. The antitumor effect of lenvatinib was established by measuring tumor volumes and weights.

Results

Lenvatinib inhibited the growth of AML cells in a dose-depend

SUBMITTER: Feng F 

PROVIDER: S-EPMC6762047 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature